Body mass index and clinical response to infliximab in rheumatoid arthritis

Ruth Klaasen, Carla A. Wijbrandts, Daniëlle M. Gerlag, +1

Arthritis & Rheumatism

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

Maarten Boers, Linda Hartman, Daniela Opriș-Belinski, +16

Annals of the Rheumatic Diseases

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study

Ruth Klaasen, Rogier M. Thurlings, Carla A. Wijbrandts, +4

Arthritis & Rheumatism

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

Ruth Klaasen, Tineke Cantaert, Carla A. Wijbrandts, +6

Lara D. Veeken

DCD donor hemodynamics as predictor of outcome after kidney transplantation

Hessel Peters‐Sengers, Julia Houtzager, Martin B.A. Heemskerk, +9

American Journal of Transplantation

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis

Ruth Klaasen, Marieke M. J. Herenius, Carla A. Wijbrandts, +6

Annals of the Rheumatic Diseases

Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis

Mihaela Gamala, Suzanne P. Linn-Rasker, Maarten Nix, +5

Clinical Rheumatology

The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis

Mihaela Gamala, Johannes W. G. Jacobs, Suzanne F Linn-Rasker, +5

Lara D. Veeken

Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count

Linda Hartman, Maurizio Cutolo, Reinhard Bos, +13

Lara D. Veeken

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

Abdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, +16

Annals of the Rheumatic Diseases